|Bid||74.32 x 800|
|Ask||79.94 x 900|
|Day's range||75.02 - 76.98|
|52-week range||67.13 - 131.73|
|Beta (5Y monthly)||1.14|
|PE ratio (TTM)||56.75|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
It is hard to get excited after looking at Edwards Lifesciences' (NYSE:EW) recent performance, when its stock has...
Shares of medical device maker Edwards Lifesciences (NYSE: EW) fell 16.6% through 11:45 a.m. ET on Friday even though the company missed analyst targets for third-quarter earnings last night by only the slimmest of margins. Analysts had forecast that Edwards would show earnings per share (EPS) of $0.62 on sales of $1.33 billion in last night's report. In constant dollars, Edwards says its sales would have grown 7%.
Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.